FDA schedules ob/gyn panel
This article was originally published in The Gray Sheet
Executive SummaryFemale Health's PMA for the FC2 second generation female condom will go before FDA's Obstetrics and Gynecology Devices advisory panel May 16, the agency announces March 27 in the Federal Register. The firm's first-generation FC is the only product for women approved by FDA that provides dual protection against unintended pregnancy and sexually transmitted diseases, according to Female Health. The second-generation device is made of nitrile while the FC is made of polyurethane
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.